{"product_id":"ocul-bcg-matrix","title":"(OCUL) Ocular Therapeutix, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Ocular Therapeutix, Inc. BCG Matrix helps you see how the company’s products or business units may fall across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The content on this page is a real preview of the actual analysis, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA 2023 allergic conjunctivitis label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXTENZA got U.S. approval for allergic conjunctivitis in 2023, widening its use beyond post-surgical eye pain and inflammation. That made it Ocular Therapeutix’s clearest growth extension in the marketed portfolio and the key Star candidate in the BCG Matrix. The expanded label taps a much larger allergy market, while the brand still builds on its established physician familiarity and commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA 2018 post-surgical inflammation and pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXTENZA, approved in 2018 for post-surgical ocular inflammation and pain, gives Ocular Therapeutix a real revenue base in a repeat-use market. The U.S. alone sees over 4 million cataract surgeries each year, and DEXTENZA can be used across recurring ophthalmic procedures. That steady procedure flow gives the product room to grow beyond its current installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnly marketed prescription brand DEXTENZA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXTENZA is Ocular Therapeutix’s only marketed prescription drug, so the company’s commercial story depends heavily on one brand. That concentration makes the franchise strategically important in a BCG Matrix, because it carries most of the company’s current sales engine and execution risk. In practice, the 2025 commercial effort is centered on one product, not a broad portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHydrogel sustained-release platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix’s bioresorbable hydrogel is the core Stars asset: it enables sustained eye-drug release, and that matters because adherence to chronic ophthalmic therapy often falls below 50%. The platform already powers DEXTENZA, so it can support multiple future launches without rebuilding the delivery system. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore platform, not a one-off product\u003c\/li\u003e\n\u003cli\u003eFits high-need adherence gap\u003c\/li\u003e\n\u003cli\u003eCan scale across new launches\u003c\/li\u003e\n\u003cli\u003eStar if new approvals keep coming\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegeneron VEGF retinal collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix's Regeneron retinal tie-up is a Star in the BCG mix because it pairs hydrogel delivery with VEGF-targeting drugs for wet AMD, a market that is still one of the biggest in retina care. Regeneron’s Eylea franchise passed $9 billion in peak annual sales, showing the scale of anti-VEGF demand. If this delivery platform extends durability, it could win share fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWet AMD is a large, recurring market.\u003c\/li\u003e\n\u003cli\u003eVEGF blockade remains standard care.\u003c\/li\u003e\n\u003cli\u003eLonger dosing can lift adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA Powers Ocular Therapeutix’s Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDEXTENZA is Ocular Therapeutix’s Star: it had U.S. approval for allergic conjunctivitis in 2023, adding to its 2018 post-surgical use and widening its addressable market. The brand is tied to a U.S. cataract market of over 4 million procedures a year, so near-term growth can stay strong. It is the company’s only marketed drug, so execution matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eKey 2025\/2026 facts\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eDEXTENZA\u003c\/td\u003e\n\u003ctd\u003e2018 launch; 2023 allergy label; over 4M U.S. cataract surgeries\u003c\/td\u003e\n\u003ctd\u003eLargest current growth engine\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOcular Therapeutix BCG Matrix pinpoints which therapies to invest in, hold, or divest amid eye-care market shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix mapping Ocular Therapeutix’s pipeline to quickly spot growth stars and cash drags.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Ocular Therapeutix, Inc., helping users verify claims quickly and make better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA U.S. sales franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXTENZA is Ocular Therapeutix, Inc.’s main commercial revenue source in the U.S., so it fits the cash cow profile. It is already FDA-approved and marketed, which means the brand can keep generating cash without heavy launch spend. That recurring U.S. franchise supports funding for newer pipeline programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-surgical ophthalmology demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-surgical eye inflammation and pain are recurring needs after routine ophthalmic surgery, and Ocular Therapeutix, Inc.'s DEXTENZA is already FDA approved for both. With more than 4 million cataract procedures done in the U.S. each year, the demand base is large and repeatable. That makes this a mature market with steady sales potential, not a frontier spend story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergic conjunctivitis repeat use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllergic conjunctivitis is recurring and seasonal, with allergic conjunctivitis affecting about 15% to 40% of people worldwide. DEXTENZA’s 2023 label expansion added ocular itching tied to allergic conjunctivitis, giving Ocular Therapeutix, Inc. another repeat-use commercial outlet. That makes mature spring and fall demand a steadier cash-cow style revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty pharmacy and physician channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix already runs an ophthalmology-focused specialty pharmacy and physician channel built for DEXTENZA, and that setup can behave like a cash cow once fixed launch costs are in place. In Q1 2025, DEXTENZA net product revenue was $10.5 million, up 7% year over year, showing the channel is still producing recurring pull-through.\u003c\/p\u003e\n\u003cp\u003eBecause this channel is already embedded with eye-care prescribers and refill workflows, each added prescription should carry lower incremental selling cost than a new launch. The model matters: established channels usually turn from cash users into cash generators after coverage, stocking, and field-force costs are absorbed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilt around DEXTENZA launch and refills\u003c\/li\u003e\n\u003cli\u003eSupports repeat prescriptions and physician pull-through\u003c\/li\u003e\n\u003cli\u003eQ1 2025 DEXTENZA revenue: $10.5 million\u003c\/li\u003e\n\u003cli\u003eRecurring channel can scale with lower added cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHydrogel manufacturing base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix has years of experience making bioresorbable ophthalmic inserts, and that scale makes Hydrogel manufacturing a cash cow support function. A built-out plant lowers unit cost and cuts incremental commercial effort, so each extra order needs less new spending. In FY2025, that kind of fixed-base leverage is what supports stronger cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYears of insert-making know-how\u003c\/li\u003e\n\u003cli\u003eLower marginal commercial effort\u003c\/li\u003e\n\u003cli\u003eSupports cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a BCG cash cow, the key is efficiency, and Hydrogel manufacturing fits that profile because the base is already in place. It turns process control and capacity into repeatable output, not heavy new capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA: Ocular’s Steady Revenue Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDEXTENZA is Ocular Therapeutix, Inc.’s clear cash cow: an FDA-approved U.S. product with recurring demand in post-surgical inflammation, pain, and allergic conjunctivitis. Q1 2025 DEXTENZA net product revenue was $10.5 million, up 7% year over year, showing steady pull-through from an established channel. Its existing physician and specialty-pharmacy base keeps incremental selling costs lower than a new launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow Item\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEXTENZA Q1 2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$10.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore use cases\u003c\/td\u003e\n\u003ctd\u003ePost-surgical inflammation, pain, allergic conjunctivitis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eOcular Therapeutix, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Ocular Therapeutix, Inc. BCG Matrix report that will be delivered after purchase. What you see here is the final document—no demo pages, no hidden changes, and no watermarks. Once purchased, you'll receive the same polished, ready-to-use file for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReSure Sealant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReSure Sealant is an FDA-approved ophthalmic device used to seal corneal incisions after cataract surgery, so its market is tightly limited to one narrow use case. That small addressable base and low use volume point to weak expansion potential, which is why it fits Ocular Therapeutix, Inc.'s Dogs bucket in the BCG Matrix. Its value is more niche than scalable, with limited room to drive material growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCataract incision leakage niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cataract incision leakage niche targets a specific postoperative wound-seal problem, but cataract surgery is a mature, standardized field, with tens of millions of procedures done globally each year. That leaves a narrow addressable slice, so growth and scale stay limited even if the medical need is real. In BCG terms, this fits Dogs: low expansion potential, small niche demand, and weak room for share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use surgical adjunct\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReSure is a one-time surgical adjunct, so it does not create recurring revenue like a chronic eye drop or implant. That limits repeat sales and keeps lifetime value per patient low. In BCG terms, its niche use and narrow procedural demand fit the Dogs bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy commercial asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReSure is a legacy commercial asset in Ocular Therapeutix’s older base, while the Company’s capital and attention are now on DEXTENZA and the pipeline. In BCG terms, that makes ReSure fit the dog quadrant: low growth, limited strategic focus, and a smaller role versus the core franchise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy, non-core asset\u003c\/li\u003e\n\u003cli\u003eLower strategic priority\u003c\/li\u003e\n\u003cli\u003eDog quadrant fit\u003c\/li\u003e\n\u003cli\u003eFocus stays on DEXTENZA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow strategic priority by end 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Ocular Therapeutix, Inc. is focused on late-stage assets, so ReSure sits low on the priority list. It is an older FDA-cleared surgical sealant, but it does not shape the growth story the way OTX-TKI and other phase 3 programs do, so its limited growth profile fits the Dog bucket.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow strategic focus by end-2025\u003c\/li\u003e\n\u003cli\u003eOlder product, limited growth\u003c\/li\u003e\n\u003cli\u003eLate-stage pipeline drives value\u003c\/li\u003e\n\u003cli\u003eDog category matches low priority\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReSure Sealant: A Narrow, Low-Growth Dog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReSure Sealant is a one-use, FDA-approved surgical sealant for corneal incision leaks, so its revenue pool stays narrow and repeat sales are weak. With Ocular Therapeutix, Inc. putting more capital into DEXTENZA and late-stage programs, ReSure looks like a low-growth, non-core Dog. Its niche role and limited scale leave little room to move the needle.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eReSure Sealant\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse case\u003c\/td\u003e\n\u003ctd\u003eSingle-use cataract adjunct\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue profile\u003c\/td\u003e\n\u003ctd\u003eNon-recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic priority\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG fit\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTX-TKI Phase 1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTX-TKI is an axitinib intravitreal implant in Phase 1, so it is still early and has no commercial share yet. Wet AMD is a large retinal market, affecting about 20 million people worldwide and driving multi-billion-dollar treatment demand. That mix of high upside and no revenue makes OTX-TKI a clear question mark in Ocular Therapeutix, Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTX-TIC Phase 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTX-TIC is Ocular Therapeutix, Inc.'s Phase 2 travoprost intracameral implant, aimed at long-acting pressure control in glaucoma and ocular hypertension. Glaucoma affects more than 80 million people worldwide, and ocular hypertension is a major at-risk pool, so the market is large. Still, the asset is a Question Mark in the BCG Matrix because it needs stronger clinical proof and real-world adoption before it can compete with established drops and sustained-release options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTX-CSI Phase 2 completed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTX-CSI, Ocular Therapeutix, Inc.'s cyclosporine intracanalicular insert for dry eye disease, has completed Phase 2, which de-risks the program but does not prove commercial success. Dry eye is a large, crowded market with millions of patients and strong rivals, so the asset still needs Phase 3 data to show clear differentiation. That makes OTX-CSI a classic Question Mark: high upside, but still unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOTX-DED Phase 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOTX-DED is Ocular Therapeutix, Inc.’s dexamethasone intracanalicular insert in Phase 2 for temporary dry eye relief. That makes it a classic Question Mark in the BCG Matrix: promising demand, but still early and unproven commercially. With no approved revenue from OTX-DED yet, the asset still needs clear clinical and regulatory wins to move up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2 = high uncertainty\u003c\/li\u003e\n\u003cli\u003eDry eye relief target\u003c\/li\u003e\n\u003cli\u003eNo approved sales yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMosaic dry AMD discovery collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Mosaic Biosciences collaboration is a discovery-stage dry AMD program, so it has no market share yet and sits in the high-uncertainty \"Question Marks\" box. Dry AMD remains a large target, with about 1.96 million U.S. patients and one approved drug class for geographic atrophy, so a lead asset could matter a lot if the science lands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiscovery only; no sales yet\u003c\/li\u003e\n\u003cli\u003eHigh failure risk, low current share\u003c\/li\u003e\n\u003cli\u003eNeeds a lead asset to move to \"Star\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Ocular Therapeutix, Inc., this is a pipeline option, not a cash driver, so value depends on data, timelines, and partner follow-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcular Therapeutix’s Early-Stage Pipeline: High Potential, No Sales Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc.'s Question Marks are early-stage pipeline bets: OTX-TKI, OTX-TIC, OTX-CSI, OTX-DED, and the Mosaic Biosciences dry AMD program. They target large markets, but none has approved sales yet, so value depends on Phase 1\/2 and later data, not current share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTX-TKI\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTX-TIC\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTX-CSI\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTX-DED\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234753487113,"sku":"ocul-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ocul-bcg-matrix.webp?v=1785727243","url":"https:\/\/dcfanalyst.com\/products\/ocul-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}